New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
14:02 EDTVIVOMeridian granted special 510(k) clearance for TRU FLU in H7N9
Meridian Bioscience announced that the company’s TRU FLU assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens. The novel avian Influenza A strain H7N9 was first reported in China last March. Since then, there have been 147 confirmed human cases of avian influenza A H7N9, with 47 deaths reported in China, the company said.
News For VIVO From The Last 14 Days
Check below for free stories on VIVO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
08:17 EDTVIVOMeridian Bioscience reaffirms FY14 EPS view 85c-90c, consensus 88c
Reaffirms FY14 revenue view $190M-$195M, consensus $192.97M. Says financial condition is "sound."
08:16 EDTVIVOMeridian Bioscience reports Q3 EPS 21c, consensus 23c
Subscribe for More Information
July 22, 2014
07:08 EDTVIVOLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use